Board of Directors
Roderick Carter, MD
Chairman of the Board
Dr. Carter has a strong history of contributions to healthcare through clinical, research, business and people leadership. He has significant experience developing and commercializing nutraceutical and pharmaceutical products and has successfully led clinical research and business development strategies for cardiovascular and inflammation related diseases. Dr. Carter is currently Principal at Aquila Life Sciences LLC, a consulting firm he founded in April 2008 focusing on pharmaceutical development and commercialization. Prior to this, he was Vice President of Clinical Development at Reliant Pharmaceuticals, which developed the OM3 cardiovascular drug LOVAZA, and today is a wholly-owned subsidiary of GlaxoSmithKline. He also served as Executive Director at Merck and Co., USA, President and Chief Executive Officer of WellGen and Senior Medical Director at Pfizer Inc., USA. Dr. Carter received his Medical Degree from the University of Witwatersrand, Johannesburg, along with a Master of Science degree in Sports Medicine from Trinity College, Dublin.
Ms. D’Alvise has extensive experience the life science industry, having held executive positions in companies commercializing pharmaceuticals, diagnostics, medical devices, and drug discovery research tools. Prior to joining Acasti in mid-2016, Ms. D’Alvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. D’Alvise was the CEO of the Sidney Kimmel Cancer Center (SKCC), a drug discovery research institute, the Co-Founder/President/CEO/Chairman of NuGEN, Inc., and the Co-Founder and Executive VP/COO of Metrika Inc. Ms. D’Alvise built NuGEN and Metrika from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to her experience as an entrepreneur, Ms. D’Alvise held the positions of VP of Drug Development at Syntex/Roche and Business Unit Director of their Pain and Inflammation business, and VP of Commercial Operations at SYVA (Syntex’s clinical diagnostics division). She began her career with Diagnostic Products Corporation where she ran global sales, marketing and service. Ms. D’Alvise has a B.S. in Biochemistry from Michigan Technological University. She has completed post-graduate work at the University of Michigan, Stanford University, and the Wharton Business Schools. Ms. D’Alvise has served on the board of numerous private companies and non-profits, and is an Entrepreneur-in-Residence for the von Liebig Institute for Entrepreneurship at the University of California, San Diego.
Mr. Canan is an accomplished business executive with over 34 years of strategic, business development and financial leadership experience. Mr. Canan recently retired from Merck & Co., Inc. where his last senior position was as Senior Vice-President, Global Controller, and Chief Accounting Officer for Merck from November 2009 to March 2014. He has managed all interactions with the audit committee of the Merck board of directors, while participating extensively with the main board and the compensation & benefits committee. Mr. Canan serves as a director of REV Group, a public company, where he chairs the audit committee. Mr. Canan also provides consulting services to Willow BioPharma, a Canadian start-up, engaged in the acquisition and development of legacy pharmaceutical assets. He also serves on the board of trustees of Angkor Hospital for Children, where he also chairs the audit & risk committee. Mr. Canan is a graduate of McGill University, Montreal, Canada, and is a Canadian Chartered Accountant.
Scientific Advisory Board
Barry A. Franklin, Ph.D.
Dr. Franklin is currently director of preventive cardiology and cardiac rehabilitation at William Beaumont Hospital. He holds professorial appointments at Oakland University, William Beaumont School of Medicine and Wayne State University, Department of Physiology, School of Medicine. During his tenure at William Beaumont Hospital, the cardiac rehabilitation program and stress testing laboratories have achieved national and international recognition in the treatment and evaluation of coronary artery disease. Dr. Franklin and his associates have studied the physiologic responses to numerous occupational and leisure-time activities, as well as the primary and secondary prevention of heart disease, comprehensive cardiovascular risk reduction, obesity and metabolism, exercise testing and prescription, lipids and lipoproteins. He has served in multiple volunteer advisory roles for the American Heart Association, and was past president of the American College of Sports Medicine and American Association of Cardiovascular and Pulmonary Rehabilitation. Dr. Franklin holds various editorial board appointments with scientific and clinical journals and has written or edited nearly 600 publications, including 481 papers, 85 book chapters, and 27 books. He has received a number of honors and awards, and he lectures extensively, both nationally and internationally, on topics related to preventive cardiology and lifestyle medicine. Dr. Franklin obtained his Ph.D. in Physiology, with a minor in Health and Physical education from Pennsylvania State University.
Robert Hegele, M.D.
Dr. Hegele is a distinguished university professor at Western University, and director of London Regional Genomics Centre at Robarts Research Institute in London, Canada. He holds the Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Chair in Human Genetics and the Blackburn Chair in Cardiovascular Research. He cares for more than 2000 patients in his lipid clinic at University Hospital, where he is a staff endocrinologist. He was among the first doctors in North America to use five medications that are now routinely prescribed to treat high cholesterol or diabetes and his laboratory discovered the molecular genetic basis of more than 20 human diseases, including familial lipid disorders and inherited diabetes. He has published over 600 papers, which have been cited more than 20,000 times in the medical literature, and he was listed in the ISI database of the top 1% of highly cited scientists in the world. Dr. Hegele has contributed to national clinical practice guidelines for lipids, blood pressure and diabetes, and to international guidelines on familial hypercholesterolemia and hypertriglyceridemia. He has trained many physicians, medical students and graduate students. Dr. Hegele obtained his medical doctorate from the University of Toronto.